pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,494 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT973Endpoints742BioPharma Dive283BioSpace183Fierce Biotech173onclive165globenewswire health73raps65
therapy area
allOncology5647Rare Disease1253Cardiology1059Hematology945Immunology937Vaccines823Pulmonology
  • STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more
    The nonprofit Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug, Luvelta
    STAT · 2mo ago↗ source
  • Chile offers new data on food warning label efficacy
    Kennedy's "publicly" "available" "calendar," drinking during pregnancy, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Opinion: I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule
    “American science is too valuable to be turned into a political football,” writes David J. Skorton, president of the Association of American Medical Colleges.
    STAT · 2mo ago
← prev
page 31 of 60
next →
fda recalls41
fda medwatch32
fda press25
797
Psychiatry & CNS693
Ophthalmology348
Endocrinology & Metabolism342
Pain342
Infectious Disease334
↗ source
  • Opinion: Ebola outbreak response requires engaging with religious traditions and leaders
    “Failing to engage religious and traditional leaders in meaningful ways was a grave misstep in previous Ebola outbreaks,” researchers write.
    STAT · 2mo ago↗ source
  • STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
    Hospital execs agree that affordability is a major issue. What to do about it is less clear.
    STAT · 2mo ago↗ source
  • How a diabetes conference sparked a controversy
    Many in the diabetes research community expressed shock and disbelief that their colleagues were threatened with arrest for passing out paper copies of an editorial.
    STAT · 2mo ago↗ source
  • STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
    STAT is tracking goals and promises of Robert F. Kennedy Jr. and his Make America Healthy Again movement — successes, incompletes, and fails.
    STAT · 2mo ago↗ source
  • STAT+: An obesity drug deep-dive, and peptides move mainstream
    Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…
    STAT · 2mo ago↗ source
  • RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
    None of STAT's requests for Kennedy's schedule have been completed, and some haven't even been acknowledged.
    STAT · 2mo ago↗ source
  • Drinking during pregnancy rose after 2020, new CDC data suggest
    A new CDC report underscores that drinking during pregnancy, while generally thought of as a thing of the past, is still a matter of concern.
    STAT · 2mo ago↗ source
  • STAT+: AMA and lawmakers push back on AI care denials
    In this edition of STAT Health Tech: HHS watchdog on denials by health insurers, lawmakers target AI denials, and Talkspace's new chatbot offering.
    STAT · 2mo ago↗ source
  • Nonprofit buys experimental cancer drug to maintain patient access
    In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.
    STAT · 2mo ago↗ source
  • Study highlights influence of socioeconomic status on children’s brain development
    A new study found that the leading environmental factor influencing brain structure and function is the socioeconomic status of a child's family.
    STAT · 2mo ago↗ source
  • STAT+: Abridge inks deals with Nvidia and Lilly
    Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
    STAT · 2mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.
    BioPharma Dive · 2mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: A suspicious denial pattern in Medicare Advantage
    Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
    STAT · 2mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Novartis doubles down on molecular glue strategy
    Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
    More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
    STAT · 2mo ago↗ source
  • STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
    A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.
    STAT · 2mo ago↗ source
  • STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
    Proving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.
    STAT · 2mo ago↗ source
  • HHS responds coolly to paper on alcohol risk
    Soda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
    BioPharma Dive · 2mo ago↗ source